Rituximab biosimilar (Amgen)

利妥昔单抗生物类似药（安进）

Report date: 2023/05/06 09:02:27

Base Information

Drug NameRituximab biosimilar (Amgen)
Drug Alias Name利妥昔单抗生物仿制药（安进）Rituximabum (Amgen)Rituximab-arrxRiabniABP-798 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmLymphoproliferative DisordersAnemia +[23] 
Global Approved IndicationsMicroscopic PolyangiitisGranulomatosis with PolyangiitisLymphoma, Follicular +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/12/17
Country/TerritoryCzechiaBulgariaCanada +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesWake Forest University Health SciencesNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[5] 
Inactive CompaniesRutgers University
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmAnemiaMicroscopic Polyangiitis +[18] 
Inactive IndicationsLymphoproliferative DisordersLymphoma, T-CellLymphoma, B-Cell, Marginal Zone +[5] 

Other Information

ATC CodeL01XC02
Related LinksN/A